Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

DMAC - DiaMedica Therapeutics Inc.

IEX Last Trade
5.415
0.080   1.477%

Share volume: 4,125
Last Updated: Fri 27 Dec 2024 08:29:21 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.25%

PREVIOUS CLOSE
CHG
CHG%
$5.34
0.08
1.50%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 25%
Dept financing 5%
Liquidity 50%
Performance 16%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.65%
1 Month
2.50%
3 Months
27.75%
6 Months
75.08%
1 Year
84.78%
2 Year
249.02%
Key data
Stock price
$5.42
P/E Ratio 
0.00
DAY RANGE
$5.30 - $5.40
EPS 
$0.00
52 WEEK RANGE
$2.29 - $6.41
52 WEEK CHANGE
$88.03
MARKET CAP 
167.999 M
YIELD 
N/A
SHARES OUTSTANDING 
42.748 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
BETA 
0.60
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$115,674
AVERAGE 30 VOLUME 
$110,946
Company detail
CEO: Rick J. Pauls
Region: US
Website: diamedica.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

DiaMedica Therapeutics Inc. develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein. DM199 is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes.

Recent news